Halozyme Therapeutics, Inc. ( HALO) - Key Metrics
HALO Revenue per Share metrics
| Date | Revenue per Share | Net Income per Share | Operating Cash Flow | Free Cash Flow per Share |
|---|---|---|---|---|
| 2026Q1 | ? | ? | ? | ? |
| 2025Q4 | $3.84 | -$1.20 | $1.86 | $1.85 |
| 2025Q3 | $3.02 | $1.49 | $1.52 | $1.50 |
| 2025Q2 | $2.68 | $1.36 | $0.82 | $0.81 |
| 2025Q1 | $2.15 | $0.96 | $1.25 | $1.24 |
HALO Payout ratio and Price per Earnings ratio
| Date | Payout ratio | PE ratio |
|---|---|---|
| 2026Q1 | ? | ? |
| 2025Q4 | ? | -13.98 |
| 2025Q3 | ? | 12.27 |
| 2025Q2 | ? | 9.55 |
| 2025Q1 | ? | 16.64 |
HALO Free Cash Flow Yield and Dividend Yield
| Date | Free Cash Flow Yield | Dividend Yield |
|---|---|---|
| 2026Q1 | 2.31% | ? |
| 2025Q4 | 2.75% | ? |
| 2025Q3 | 2.04% | ? |
| 2025Q2 | 1.55% | ? |
| 2025Q1 | 1.95% | ? |
HALO
Price: $70.90
52 week price:
Payout Ratio Range:
Earnings Per Share: 2.85 USD
P/E Ratio: 23.55
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 402302
Ebitda: 127.5 millionMarket Capitalization: 8.5 billion